Umecrine Cognition is developing pharmaceuticals against neurological disorders in the central nervous system, CNS that are caused by endogenous CNS-active steroids (GABA-steroids). The company is focused on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease, a growing area with high unmet medical need.

 

Hepatic Encephalopathy is a serious neuropsychiatric and neurocognitive complication in acute and chronic liver disease ranging from minimal to overt Hepatic Encephalopathy, characterized by impaired cognitive and motor functions and with symptoms ranging from disorientation through coma.

 

The company's therapy represents a new target class aimed to treat life-threatening overt Hepatic Encephalopathy and long-term treatment in minimal Hepatic Encephalopathy. The current lack of therapeutics that directly addresses the neurocognitive signs and symptoms of Hepatic Encephalopathy makes a novel treatment likely to become a major contribution for the treatment of this disorder.